3月14日,金斯瑞生物科技(01548)发布公告,传奇生物科技股份有限公司截至2024年12月31日的第四季度及全年财务业绩显示,2024年第四季度净贸易销售额约为3.34亿美元,全年销售额为9.63亿美元。公司表示,已有超过5000例患者接受了CARVYKTI®治疗,且该产品已在诺华生产基地启动商业化生产。截至2024年12月31日,传奇生物的现金及现金等价物、定期存款达11亿美元,预计将支持...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.